Tegal has been in business for 40 years, with a current focus on emerging technologies in the healthcare sector. The company's process and equipment know-how has been incorporated into devices fabricated by some of the world's leading semiconductor and microelectromechanical systems (NASDAQ:MEMS) companies, including its one-time parent firm, Motorola.
The company announced today that it expects to appoint James Karis as Co-CEO of Tegal and also a director of the firm. The appointment will effective upon completion of the deal to acquire CollabRx Inc., where Mr. Karis serves as CEO and director. CollabRx is a privately-held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine with a particular focus on cancer.
Mr. Karis, who became CollabRx CEO in 2011, served for nine years as president and CEO of Entelos, a US-based life sciences technology company. Prior to that, he held a number of important senior positions at several companies, including president and chief operating officer of PAREXEL International, COO of Pharmaco International, and vice-president of international operations at Baxter International. Mr. Karis also co-founded KMR Group, a leading pharmaceutical research and development benchmarking consulting firm.
The incoming Mr. Karis will join Tegal's chairman, president, and current CEO Thomas Mika in the Co-CEO role. Upon completion of the transaction and following Tegal's annual meeting in September, the combined company will conduct business under the CollabRx name.
For additional information about Tegal Corporation and the proposed deal, please visit the company's website at tegal.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net